{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:24:19Z","timestamp":1782973459962,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13171-3","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:35:09Z","timestamp":1778232909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Hanie","family":"Sakhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Meskini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Sheikhpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"13171_CR1","doi-asserted-by":"crossref","unstructured":"Iacobino A, Fattorini L, Giannoni F. Drug-resistant tuberculosis 2020: where we stand. Pathogens. 2020;10(6):2153.","DOI":"10.3390\/app10062153"},{"issue":"2","key":"13171_CR2","first-page":"126","volume":"20","author":"M Sheikhpour","year":"2021","unstructured":"Sheikhpour M, Shokrgozar MA, Biglari A, Pornour M, Abdolrahimi F, Poorazar Dizaji S, et al. Gene Expression and In Vitro Pharmacogenetic Studies of Dopamine and Serotonin Gene Receptors in Tuberculosis. Tanaffos. 2021;20(2):126\u201333.","journal-title":"Tanaffos"},{"issue":"1","key":"13171_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","volume":"12","author":"N Salari","year":"2023","unstructured":"Salari N, Kanjoori AH, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis poverty. 2023;12(1):57.","journal-title":"Infect Dis poverty"},{"key":"13171_CR4","doi-asserted-by":"crossref","unstructured":"Mbewana Ntshanka NG, Msagati TAM. Trends and progress on antibiotic-resistant Mycobacterium tuberculosis and genes in relation to human immunodeficiency virus. Can J Infect Dis Med Microbiol. 2023;2023:6659212.","DOI":"10.1155\/2023\/6659212"},{"issue":"null","key":"13171_CR5","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.2147\/IJN.S251524","volume":"15","author":"S Zomorodbakhsh","year":"2020","unstructured":"Zomorodbakhsh S, Abbasian Y, Naghinejad M, Sheikhpour M. The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on Mycobacterium tuberculosis. Int J Nanomed. 2020;15(null):5901\u20139.","journal-title":"Int J Nanomed"},{"key":"13171_CR6","doi-asserted-by":"crossref","unstructured":"Kostyukova I, Pasechnik O, Mokrousov I. Epidemiology and Drug Resistance Patterns of Mycobacterium tuberculosis in high-burden area in Western Siberia, Russia. Microorganisms. 2023;11(2).","DOI":"10.3390\/microorganisms11020425"},{"key":"13171_CR7","doi-asserted-by":"crossref","unstructured":"Nieto Ramirez LM, Quintero Vargas K, Diaz G. Whole genome sequencing for the analysis of drug-resistant strains of Mycobacterium tuberculosis: a systematic review for bedaquiline and delamanid. Antibiotics (Basel Switzerland). 2020;9(3).","DOI":"10.3390\/antibiotics9030133"},{"issue":"1","key":"13171_CR8","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/ncomms4369","volume":"5","author":"A Koul","year":"2014","unstructured":"Koul A, Vranckx L, Dhar N, G\u00f6hlmann HWH, \u00d6zdemir E, Neefs J-M, et al. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun. 2014;5(1):3369.","journal-title":"Nat Commun"},{"issue":"5","key":"13171_CR9","doi-asserted-by":"publisher","first-page":"e0217169","DOI":"10.1371\/journal.pone.0217169","volume":"14","author":"M Karmakar","year":"2019","unstructured":"Karmakar M, Rodrigues CHM, Holt KE, Dunstan SJ, Denholm J, Ascher DB. Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. PLoS ONE. 2019;14(5):e0217169.","journal-title":"PLoS ONE"},{"issue":"7","key":"13171_CR10","doi-asserted-by":"publisher","first-page":"e0153222","DOI":"10.1128\/aac.01532-22","volume":"67","author":"J Xu","year":"2023","unstructured":"Xu J, Li D, Shi J, Wang B, Ge F, Guo Z, et al. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. Antimicrob Agents Chemother. 2023;67(7):e0153222.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"13171_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/eva.12654","volume":"11","author":"QH Nguyen","year":"2018","unstructured":"Nguyen QH, Contamin L, Nguyen TVA, Ba\u00f1uls AL. Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis. Evol Appl. 2018;11(9):1498\u2013511.","journal-title":"Evol Appl"},{"issue":"1","key":"13171_CR12","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1038\/s41598-022-13682-4","volume":"12","author":"M Sheikhpour","year":"2022","unstructured":"Sheikhpour M, Delorme V, Kasaeian A, Amiri V, Masoumi M, Sadeghinia M, et al. An effective nano drug delivery and combination therapy for the treatment of Tuberculosis. Sci Rep. 2022;12(1):9591.","journal-title":"Sci Rep"},{"issue":"4","key":"13171_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1128\/JCM.01662-16","volume":"55","author":"B Tessema","year":"2017","unstructured":"Tessema B, Nabeta P, Valli E, Albertini A, Collantes J, Lan NH, et al. FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance. J Clin Microbiol. 2017;55(4):1066\u201373.","journal-title":"J Clin Microbiol"},{"issue":"2","key":"13171_CR14","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/S2666-5247(23)00317-8","volume":"5","author":"C Nimmo","year":"2024","unstructured":"Nimmo C, Bionghi N, Cummings MJ, Perumal R, Hopson M, Al Jubaer S, et al. Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. Lancet Microbe. 2024;5(2):e164\u201372.","journal-title":"Lancet Microbe"},{"key":"13171_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2023.05.001","volume":"34","author":"Q An","year":"2023","unstructured":"An Q, Lin R, Yang Q, Wang C, Wang D. Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. J global Antimicrob Resist. 2023;34:214\u201326.","journal-title":"J global Antimicrob Resist"},{"issue":"11","key":"13171_CR16","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","volume":"2","author":"N Ismail","year":"2021","unstructured":"Ismail N, Rivi\u00e8re E, Limberis J, Huo S, Metcalfe JZ, Warren RM, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe. 2021;2(11):e604\u201316.","journal-title":"Lancet Microbe"},{"issue":"1","key":"13171_CR17","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1038\/s41598-022-11795-4","volume":"12","author":"G Napier","year":"2022","unstructured":"Napier G, Khan AS, Jabbar A, Khan MT, Ali S, Qasim M, et al. Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in Pakistan. Sci Rep. 2022;12(1):7703.","journal-title":"Sci Rep"},{"issue":"1","key":"13171_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13756-021-00995-8","volume":"10","author":"C Yao","year":"2021","unstructured":"Yao C, Guo H, Li Q, Zhang X, Shang Y, Li T, et al. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Antimicrob Resist Infect control. 2021;10(1):126.","journal-title":"Antimicrob Resist Infect control"},{"issue":"12","key":"13171_CR19","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","volume":"4","author":"B Derendinger","year":"2023","unstructured":"Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R, et al. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. Lancet Microbe. 2023;4(12):e972\u201382.","journal-title":"Lancet Microbe"},{"issue":"5","key":"13171_CR20","doi-asserted-by":"publisher","first-page":"e0132423","DOI":"10.1128\/spectrum.01324-23","volume":"11","author":"Z Song","year":"2023","unstructured":"Song Z, Liu C, He W, Pei S, Liu D, Cao X, et al. Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China. Microbiol Spectr. 2023;11(5):e0132423.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"13171_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12866-022-02475-4","volume":"22","author":"DK Saeed","year":"2022","unstructured":"Saeed DK, Shakoor S, Razzak SA, Hasan Z, Sabzwari SF, Azizullah Z, et al. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ na\u00efve TB patients in Pakistan. BMC Microbiol. 2022;22(1):62.","journal-title":"BMC Microbiol"},{"key":"13171_CR22","doi-asserted-by":"publisher","first-page":"2037961","DOI":"10.1155\/2024\/2037961","volume":"2024","author":"A Rukmana","year":"2024","unstructured":"Rukmana A, Gozali C, Erlina L. Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia. Int J Microbiol. 2024;2024:2037961.","journal-title":"Int J Microbiol"},{"issue":"1","key":"13171_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12941-023-00568-0","volume":"22","author":"Y Hu","year":"2023","unstructured":"Hu Y, Fan J, Zhu D, Liu W, Li F, Li T, et al. Investigation of bedaquiline resistance and genetic mutations in multi-drug resistant Mycobacterium tuberculosis clinical isolates in Chongqing, China. Ann Clin Microbiol Antimicrob. 2023;22(1):19.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"13171_CR24","doi-asserted-by":"publisher","first-page":"e0374923","DOI":"10.1128\/spectrum.03749-23","volume":"12","author":"T Umpeleva","year":"2024","unstructured":"Umpeleva T, Chetverikova E, Belyaev D, Eremeeva N, Boteva T, Golubeva L, et al. Identification of genetic determinants of bedaquiline resistance in Mycobacterium tuberculosis in Ural region, Russia. Microbiol Spectr. 2024;12(3):e0374923.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"13171_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12879-021-06024-8","volume":"21","author":"H Zheng","year":"2021","unstructured":"Zheng H, He W, Jiao W, Xia H, Sun L, Wang S, et al. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect Dis. 2021;21(1):330.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"13171_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3343\/alm.2018.38.6.563","volume":"38","author":"JS Yang","year":"2018","unstructured":"Yang JS, Kim KJ, Choi H, Lee SH. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Annals Lab Med. 2018;38(6):563\u20138.","journal-title":"Annals Lab Med"},{"key":"13171_CR27","doi-asserted-by":"crossref","unstructured":"Cannas A, Butera O, Mazzarelli A, Messina F, Vulcano A, Parracino MP, et al. Implementation of whole genome sequencing of tuberculosis isolates in a referral center in Rome: six years\u2019 experience in characterizing drug-resistant TB and disease transmission. Antibiotics (Basel). 2024;13(2).","DOI":"10.3390\/antibiotics13020134"},{"key":"13171_CR28","doi-asserted-by":"publisher","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","volume":"12","author":"SH Wu","year":"2021","unstructured":"Wu SH, Chan HH, Hsiao HC, Jou R. Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. Front Microbiol. 2021;12:754249.","journal-title":"Front Microbiol"},{"issue":"3","key":"13171_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jinf.2021.02.004","volume":"82","author":"G Wang","year":"2021","unstructured":"Wang G, Jiang G, Jing W, Zong Z, Yu X, Chen S, et al. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. J Infect. 2021;82(3):371\u20137.","journal-title":"J Infect"},{"key":"13171_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","volume":"28","author":"NA Ismail","year":"2018","unstructured":"Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine. 2018;28:136\u201342.","journal-title":"EBioMedicine"},{"key":"13171_CR31","doi-asserted-by":"crossref","unstructured":"Zhdanova S, Jiao WW, Sinkov V, Khromova P, Solovieva N, Mushkin A, et al. Insight into population structure and drug resistance of pediatric tuberculosis strains from China and Russia gained through whole-genome sequencing. Int J Mol Sci. 2023;24(12).","DOI":"10.3390\/ijms241210302"},{"issue":"5","key":"13171_CR32","doi-asserted-by":"publisher","first-page":"e0277023","DOI":"10.1128\/spectrum.02770-23","volume":"12","author":"A Bhanushali","year":"2024","unstructured":"Bhanushali A, Atre S, Nair P, Thandaseery GA, Shah S, Kuruwa S, et al. Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases. Microbiol Spectr. 2024;12(5):e0277023.","journal-title":"Microbiol Spectr"},{"issue":"11","key":"13171_CR33","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/jac\/dkad252","volume":"78","author":"S Mok","year":"2023","unstructured":"Mok S, Roycroft E, Flanagan PR, Wagener J, Fitzgibbon MM. Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. J Antimicrob Chemother. 2023;78(11):2637\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"13171_CR34","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.2147\/IDR.S429003","volume":"16","author":"E Tong","year":"2023","unstructured":"Tong E, Zhou Y, Liu Z, Zhu Y, Zhang M, Wu K, et al. Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China. Infect drug Resist. 2023;16:6951\u201363.","journal-title":"Infect drug Resist"},{"key":"13171_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijid.2020.07.044","volume":"99","author":"J Yang","year":"2020","unstructured":"Yang J, Pang Y, Zhang T, Xian X, Li Y, Wang R, et al. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. Int J Infect Dis. 2020;99:163\u201370.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"13171_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jiph.2023.11.018","volume":"17","author":"S Li","year":"2024","unstructured":"Li S, Tan Y, Deng Y, Bai G, Huang M, Shang Y, et al. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data. J Infect Public Health. 2024;17(1):137\u201342.","journal-title":"J Infect Public Health"},{"key":"13171_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jgar.2021.06.007","volume":"26","author":"W He","year":"2021","unstructured":"He W, Liu C, Liu D, Ma A, Song Y, He P, et al. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. J global Antimicrob Resist. 2021;26:241\u20138.","journal-title":"J global Antimicrob Resist"},{"key":"13171_CR38","doi-asserted-by":"crossref","unstructured":"Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017;61(10).","DOI":"10.1128\/AAC.00900-17"},{"issue":"5","key":"13171_CR39","doi-asserted-by":"publisher","first-page":"e02405","DOI":"10.1128\/spectrum.02405-21","volume":"10","author":"B Zhao","year":"2022","unstructured":"Zhao B, Liu C, Fan J, Ma A, He W, Hu Y, et al. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China. Microbiol Spectr. 2022;10(5):e02405\u201321.","journal-title":"Microbiol Spectr"},{"key":"13171_CR40","doi-asserted-by":"publisher","unstructured":"Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6). https:\/\/doi.org\/10.1128\/aac.00239.","DOI":"10.1128\/aac.00239"},{"issue":"3","key":"13171_CR41","first-page":"684","volume":"72","author":"C Villellas","year":"2016","unstructured":"Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2016;72(3):684\u201390.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"13171_CR42","doi-asserted-by":"publisher","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","volume":"73","author":"Y Liu","year":"2020","unstructured":"Liu Y, Gao M, Du J, Wang L, Gao J, Shu W, et al. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China. Clin Infect Dis. 2020;73(9):e3391\u20137.","journal-title":"Clin Infect Dis"},{"key":"13171_CR43","doi-asserted-by":"crossref","unstructured":"Chesov E, Chesov D, Maurer FP, Andres S, Utpatel C, Barilar I, et al. Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J. 2022;59(3).","DOI":"10.1183\/13993003.00621-2021"},{"issue":"9","key":"13171_CR44","doi-asserted-by":"publisher","first-page":"e0311042","DOI":"10.1371\/journal.pone.0311042","volume":"19","author":"Y Peng","year":"2024","unstructured":"Peng Y, Li C, Hui X, Huo X, Shumuyed NA, Jia Z. Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China. PLoS ONE. 2024;19(9):e0311042.","journal-title":"PLoS ONE"},{"issue":"3","key":"13171_CR45","doi-asserted-by":"publisher","first-page":"e0240523","DOI":"10.1128\/spectrum.02405-23","volume":"12","author":"HNA Blankson","year":"2024","unstructured":"Blankson HNA, Kamara RF, Barilar I, Andres S, Conteh OS, Dallenga T, et al. Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone. Microbiol Spectr. 2024;12(3):e0240523.","journal-title":"Microbiol Spectr"},{"key":"13171_CR46","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.lana.2024.100674","volume":"31","author":"C Utpatel","year":"2024","unstructured":"Utpatel C, Zavaleta M, Rojas-Bolivar D, M\u00fchlbach A, Picoy J, Portugal W, et al. Prison as a driver of recent transmissions of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study. Lancet Reg health Americas. 2024;31:100674.","journal-title":"Lancet Reg health Americas"},{"key":"13171_CR47","doi-asserted-by":"publisher","first-page":"1349715","DOI":"10.3389\/fmicb.2024.1349715","volume":"15","author":"A Liu","year":"2024","unstructured":"Liu A, Liu S, Lv K, Zhu Q, Wen J, Li J, et al. Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. Front Microbiol. 2024;15:1349715.","journal-title":"Front Microbiol"},{"issue":"1","key":"13171_CR48","doi-asserted-by":"publisher","first-page":"19602","DOI":"10.1038\/s41598-024-70471-x","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Lim DR, Phelan JE, Reyes LT, Palparan AG, Sanchez MGC, et al. Whole genome sequencing analysis of Mycobacterium tuberculosis reveals circulating strain types and drug-resistance mutations in the Philippines. Sci Rep. 2024;14(1):19602.","journal-title":"Sci Rep"},{"key":"13171_CR49","doi-asserted-by":"crossref","unstructured":"Roberts LW, Malone KM, Hunt M, Joseph L, Wintringer P, Knaggs J, et al. MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis. Lancet Microbe. 2024;5(8).","DOI":"10.1016\/S2666-5247(24)00053-3"},{"issue":"11","key":"13171_CR50","doi-asserted-by":"publisher","first-page":"100899","DOI":"10.1016\/S2666-5247(24)00131-9","volume":"5","author":"S Pei","year":"2024","unstructured":"Pei S, Song Z, Yang W, He W, Ou X, Zhao B, et al. The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis. Lancet Microbe. 2024;5(11):100899.","journal-title":"Lancet Microbe"},{"key":"13171_CR51","doi-asserted-by":"crossref","unstructured":"Nehru VJ, Brammacharry U, Ramkumar SRS, Khusro A, Vadakunnel MJ, Gunasekaran S, et al. Molecular analysis of bedaquiline resistance and genetic variations in clinical isolates of multidrug and fluoroquinolones-resistant Mycobacterium tuberculosis. J King Saud Univ Sci. 2024;36(6).","DOI":"10.1016\/j.jksus.2024.103226"},{"key":"13171_CR52","doi-asserted-by":"crossref","unstructured":"Ghajavand H, Kamakoli MK, Khanipour S, Dizaji SP, Masoumi M, Jamnani FR, et al. High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness. Antimicrob Agents Chemother. 2019;63(3).","DOI":"10.1128\/AAC.02530-18"},{"issue":"7","key":"13171_CR53","doi-asserted-by":"publisher","first-page":"e0032222","DOI":"10.1128\/aac.00322-22","volume":"66","author":"E Rivi\u00e8re","year":"2022","unstructured":"Rivi\u00e8re E, Verboven L, Dippenaar A, Goossens S, De Vos E, Streicher E, et al. Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage. Antimicrob Agents Chemother. 2022;66(7):e0032222.","journal-title":"Antimicrob Agents Chemother"},{"key":"13171_CR54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2023.04.003","volume":"33","author":"Y Shang","year":"2023","unstructured":"Shang Y, Chen S, Shi W, Nie W, Jing W, Huo F, et al. Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. J global Antimicrob Resist. 2023;33:294\u2013300.","journal-title":"J global Antimicrob Resist"},{"key":"13171_CR55","doi-asserted-by":"crossref","unstructured":"Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A, Faqirzai J, et al. Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis\u2014experiences from Armenia. Antimicrob Agents Chemother. 2025;69(5).","DOI":"10.1128\/aac.01839-24"},{"issue":"1","key":"13171_CR56","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","volume":"25","author":"X Hu","year":"2025","unstructured":"Hu X, Wu Z, Lei J, Zhu Y, Gao J. Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2025;25(1):689.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"13171_CR57","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3201\/eid3003.240134","volume":"30","author":"G G\u00fcnther","year":"2024","unstructured":"G\u00fcnther G, Mhuulu L, Diergaardt A, Dreyer V, Moses M, Anyolo K, et al. Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia. Emerg Infect Dis. 2024;30(3):568\u201371.","journal-title":"Emerg Infect Dis"},{"key":"13171_CR58","doi-asserted-by":"publisher","first-page":"807095","DOI":"10.3389\/fcimb.2022.807095","volume":"12","author":"Q Guo","year":"2022","unstructured":"Guo Q, Bi J, Lin Q, Ye T, Wang Z, Wang Z, et al. Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis. Front Cell Infect Microbiol. 2022;12:807095.","journal-title":"Front Cell Infect Microbiol"},{"key":"13171_CR59","doi-asserted-by":"publisher","first-page":"954074","DOI":"10.3389\/fcimb.2022.954074","volume":"12","author":"C Nimmo","year":"2022","unstructured":"Nimmo C, Millard J, Faulkner V, Monteserin J, Pugh H, Johnson EO. Evolution of Mycobacterium tuberculosis drug resistance in the genomic era. Front Cell Infect Microbiol. 2022;12:954074.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"13171_CR60","doi-asserted-by":"publisher","first-page":"10444","DOI":"10.1038\/s41598-023-36955-y","volume":"13","author":"J Snobre","year":"2023","unstructured":"Snobre J, Villellas MC, Coeck N, Mulders W, Tzfadia O, de Jong BC, et al. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. Sci Rep. 2023;13(1):10444.","journal-title":"Sci Rep"},{"issue":"12","key":"13171_CR61","doi-asserted-by":"publisher","first-page":"e964","DOI":"10.1016\/S2666-5247(23)00321-X","volume":"4","author":"C Lange","year":"2023","unstructured":"Lange C, Vasiliu A, Mandalakas AM. Emerging bedaquiline-resistant tuberculosis. Lancet Microbe. 2023;4(12):e964\u20135.","journal-title":"Lancet Microbe"},{"key":"13171_CR62","doi-asserted-by":"crossref","unstructured":"Mdlenyani L, Mohamed Z, Stadler JAM, Mtwa N, Meintjes G, Warren R, et al. Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study. The Lancet Infectious Diseases; 2025.","DOI":"10.1101\/2025.01.21.25320876"},{"issue":"135","key":"13171_CR63","doi-asserted-by":"publisher","first-page":"135ra67","DOI":"10.1126\/scitranslmed.3003815","volume":"4","author":"R Sergeev","year":"2012","unstructured":"Sergeev R, Colijn C, Murray M, Cohen T. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med. 2012;4(135):135ra67.","journal-title":"Sci Transl Med"},{"key":"13171_CR64","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"issue":"3","key":"13171_CR65","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2666-5247(20)30201-9","volume":"2","author":"B Cheng","year":"2021","unstructured":"Cheng B, Behr MA, Howden BP, Cohen T, Lee RS. Reporting practices for genomic epidemiology of tuberculosis: a systematic review of the literature using STROME-ID guidelines as a benchmark. Lancet Microbe. 2021;2(3):e115\u201329.","journal-title":"Lancet Microbe"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13171-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13171-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:02:16Z","timestamp":1782968536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13171-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13171"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13171-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Artificial intelligence assistance (OpenAI ChatGPT, GPT-4) was used exclusively for language editing, translation, grammar refinement, and formatting. The authors reviewed and verified all content to ensure accuracy and integrity of the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations of Generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1218"}}